Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.

Objective: The aim of this study was to evaluate the efficacy, cardiotoxicity profile and long-term benefits of neoadjuvant therapy in human epidermal growth factor receptor 2-positive operable breast cancer patients.

Patients And Methods: A total of 142 patients diagnosed from 2005 to 2016 were included in the study. The treatment consisted of a sequential regimen of taxanes and anthracyclines plus trastuzumab.

Texture analysis of high-resolution dedicated breast F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer.

Purpose: This study aims to determine whether PET textural features measured with a new dedicated breast PET scanner reflect biological characteristics of breast tumors.

Methods: One hundred and thirty-nine breast tumors from 127 consecutive patients were included in this analysis. All of them underwent a F-FDG PET scan before treatment.